NCT01499017 - A Single Dose Study Of PF-06291874 In Healthy Adult Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Healthy

Interventions

DRUG

PF-06291874 or placebo

PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 3 mg to 100 mg. Correspondingly, placebo doses will be administered as suspension.

DRUG

PF-06291874 or Placebo

PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 300 mg to 650 mg. Correspondingly, placebo doses will be administered as suspension.

Trial Locations (1)

06511

Pfizer Investigational Site, New Haven